BrainsWay’s Deep TMS Shows Early Promise in Depression and Alzheimer’s Combo Study — BrainsWay Ltd.

Event summary

BrainsWay’s Deep TMS™ pilot study reported 83.3% response rate and 50% remission rate in depressive symptoms for patients with Major Depressive Disorder (MDD) and early-stage Alzheimer’s disease.
Study observed measurable neurophysiological changes, including reduced delta power in the right temporal lobe and increased alpha coherence in brain connectivity.
Researchers from Delray Center for Brain Science and Florida Atlantic University conducted the study with 12 patients using BrainsWay’s H1 and H7 Coils.
Deep TMS is not FDA-cleared for Alzheimer’s disease treatment, requiring further controlled clinical research.

The big picture

BrainsWay’s pilot study results highlight the potential of Deep TMS to address a critical unmet need in treating depression comorbid with early-stage Alzheimer’s disease. The observed neurophysiological changes suggest the technology’s ability to modulate brain networks, positioning BrainsWay at the forefront of non-invasive neurostimulation treatments. The findings come as the mental health and neurology sectors increasingly focus on integrated solutions for co-occurring conditions, with Deep TMS emerging as a key player in this evolving landscape.

What we're watching

Clinical Validation: Whether BrainsWay can replicate these results in larger, controlled studies to support broader clinical applications.
Regulatory Pathway: The pace at which BrainsWay advances Deep TMS through FDA clearance for Alzheimer’s disease treatment.
Market Expansion: How these findings could position BrainsWay in the growing market for non-invasive treatments targeting complex neuropsychiatric conditions.